Current state of knowledge about spironolactone-induded gynecomastia. Review 2024
DOI:
https://doi.org/10.12775/QS.2024.17.53767Keywords
gynecomastia, estrogens, androgens, Breast enlargement, spironolactone, drug-induced gynecomastiaAbstract
Spironolactone, a potassium-sparing diuretic, acts as an aldosterone antagonist but also has anti-androgen properties, leading to increased estrogen levels in the body. It can cause gynecomastia in men by blocking the production of androgens, preventing androgens from binding to specific receptors, and rising levels of both total and free estrogen. Numerous scientific articles and clinical cases have been analyzed and confirmed this statement. Evidence for gynecomastia with mineralocorticoid receptor antagonist usage was of high quality.Clinicians are advised to monitor patients taking these medications for developing gynecomastia and to consider this risk in the therapeutic decision-making process.
References
Berbenetz NM, Mrkobrada M. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis. BMC Cardiovasc Disord. 2016; 16(1). https://doi.org/10.1186/s12872-016-0425-x
Beredac G. Clinical Pharmacology of Spironolactone. Journal of Diagnosis & Case Reports. 2022;1–4. https://doi.org/10.47363/JDCRS/2022(3)126
Khan JA. A Literature Review of the Pharmacokinetics, Pharmacodynamics, and Possible Uses of Spironolactone. UTSC’s Journal of Natural Sciences. 2021 ;2(1):73–82. https://doi.org/10.33137/jns.v2i1.35920
Carone L, Oxberry SG, Twycross R, Charlesworth S, Mihalyo M, Wilcock A. Spironolactone. J Pain Symptom Manage. 2017 ;53(2):288–92. https://doi.org/10.1016/j.jpainsymman.2016.12.320
Johnson RE, Murad MH. Gynecomastia: pathophysiology, evaluation, and management. Mayo Clin Proc. 2009 ; 84(11):1010–5. https://doi.org/10.1016/S0025-6196(11)60671-X
Cuhaci N, Polat SB, Evranos B, Ersoy R, Cakir B. Gynecomastia: Clinical evaluation and management. Indian J Endocrinol Metab. 2014 ;18(2):150–8. https://doi.org/10.4103/2230-8210.129104
Chatterjee S., Chatterjee S. Case Studies in Endocrynology. 2020. 81 p.
Mathur R, Braunstein GD. Gynecomastia: Pathomechanisms and Treatment Strategies. Horm Res. 1997; 48(3):95–102. https://doi.org/10.1159/000185497
Ayyavoo A. Gynecomastia. Indian J Pediatr. 2023; 90(10):1013–7. https://doi.org/10.1007/s12098-023-04810-7
Veeregowda S, Krishnamurthy J, Krishnaswamy B, Narayana S. Spironolactone-Induced Unilateral Gynecomastia. Int J Appl Basic Med Res. 2018; 8(1):45. https://doi.org/10.4103/ijabmr.IJABMR_399_16 /
Charlot M, Béatrix O, Chateau F, Dubuisson J, Golfier F, Valette PJ, et al. Pathologies of the male breast. Diagn Interv Imaging . 2013;94(1):26–37. https://doi.org/10.1016/j.diii.2012.10.011
Wasniewska M, Arrigo T, Lombardo F, Crisafulli G, Salzano G, De Luca F. 11-Hydroxylase deficiency as a cause of pre-pubertal gynecomastia. J Endocrinol Invest. 2009;32(4):387–8. https://doi.org/10.1007/B
Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-based review. Expert Opin Drug Saf. 2012 ;11(5):779–95. https://doi.org/10.1517/14740338.2012.712109
Huffman DH, Kampmann JP, Hignite CE, Azarnoff DL. Gynecomastia induced in normal males by spironolactone. Clin Pharmacol Ther. 1978 ;24(4):465–73. https://doi.org/10.1002/cpt1978244465
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 ;341(10):709–17. https://doi.org/10.1056/NEJM199909023411001
Mosenkis A, Townsend RR. Gynecomastia and Antihypertensive Therapy. The Journal of Clinical Hypertension . 2004 ;6(8):122. https://doi.org/10.1111/j.1524-6175.2004.3735.x
Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med. 1977;87(4):398–403. https://doi.org/10.7326/0003-4819-87-4-398
Trinchieri A, Perletti G, Magri V, Stamatiou K, Trinchieri M, Montanari E. Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials. Arch Ital Urol Androl. 2021; 93(4):489–96. https://doi.org/10.4081/aiua.2021.4.489
Caminos-Torres R, Ma L, Snyder PJ. Gynecomastia and semen abnormalities induced by spironolactone in normal men. J Clin Endocrinol Metab. 1977 ; 45(2):255–60. https://doi.org/10.1210/jcem-45-2-255https://doi.org/10.1210/jcem-45-2-255
Bellati G, Idéo G. Gynaecomastia after spironolactone and potassium canrenoate. Lancet. 1986; 1(8481):626. https://doi.org/10.1016/s0140-6736(86)92856-4
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17. https://doi.org/10.1056/NEJM199909023411001
Putri PGAB, Nurfitriani N, Suryawati IGA. High dose and long-term use of spironolactone induce gynecomastia in an elderly man with chronic heart failure: a case report. Intisari Sains Medis. 2021;12(1):60–3. https://doi.org/10.15562/ism.v12i1.972
Haynes BA, Mookadam F. Male Gynecomastia. Mayo Clin Proc. 2009 ;84(8):672. https://doi.org/10.4065/mcp.2010.0093
Sahera S, Vijaya Bhaskar Reddy Y, Kumar DS, Ramana V, Kusuma Kumari S. Spironolactone Induced Gynecomastia: A Case Report. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN. 2019;18:56–9. https://doi.org/10.4065/84.8.672
Cuculi F, Suter A, Erne P. Clinical Vistas Briefs: Spironolactone-induced gynecomastia. CMAJ : Canadian Medical Association Journal. 2007 ;176(5):620. https://doi.org/10.1503/cmaj.061286
Kak M, Kak VK. Unilateral Gynecomastia: Spironolactone. J Clin Exp Hepatol. 2023;13:S157. https://doi.org/10.1016/j.jceh.2023.07.138
R Louzolo-Kimbembe, Z I, S R, G EM, N EA. Etiological Difficulty of Gynecomastia in a Patient on Several Substances. Scholars Journal of Applied Medical Sciences. 2021;9(3):306–8. https://doi.org/10.36347/sjams.2021.v09i03.002
Parthasarathy HK, Ménard J, White WB, Young WF, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29(5):980–90. https://doi.org/10.1097/HJH.0b013e3283455ca5
Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001;15(1):79–87. https://doi.org/10.1023/a:1011119003788
Dimitriadis G, Papadopoulos V, Mimidis K. Eplerenone reverses spironolactone-induced painful gynaecomastia in cirrhotics. Hepatol Int. 2011 Jun;5(2):738. https://doi.org/10.1007/s12072-010-9235-x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Oliwia Kamila Iszczuk, Julia Silldorff, Tomasz Fura, Marcin Dudek, Radosław Zaucha, Magdalena Gajkiewicz, Zuzanna Felińska, Małgorzata Zając, Stanisław Anczyk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 143
Number of citations: 0
